PharmaBlock Sciences (Nanjing), Inc. Class A

PharmaBlock Sciences (Nanjing), Inc. Class A

SSZSE:300725
42.43
CNY
-0.52
(-1.21%)
0.96EPS
57.52P/E
12.94BMarket Cap
Apr 28Next Earn

Total Valuation

CNY

As of September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A carries a market capitalization of 12.94B, placing it among publicly traded companies globally. Its enterprise value stands at 11.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.94B
Enterprise Value11.57B

Important Dates

PharmaBlock Sciences (Nanjing), Inc. Class A's next confirmed earnings release is scheduled for April 28, 2027.

Earnings Date4/28/2027

Share Statistics

As of September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A has 233.81M shares outstanding.

Shares Outstanding233.81M

Valuation Ratios

As of September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A trades at a trailing price-to-earnings ratio of 57.52. The price-to-sales ratio is 5.82, and the price-to-book ratio stands at 2.82.

PE Ratio57.52
PS Ratio5.82
PB Ratio2.82
P/TBV Ratio3.14

Enterprise Valuation

As of September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A trades at an EV/EBITDA multiple of 45.58 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 45.58 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 11.57B versus a market cap of 12.94B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.29
EV / EBITDA45.58
EV / EBIT45.58

Financial Position

As of September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A maintains a current ratio of 3.70, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.55, indicating moderate leverage, while an interest coverage ratio of -537.37 demonstrates limited ability to service its debt obligations.

Current Ratio3.70
Quick Ratio1.85
Debt / Equity0.55
Debt / EBITDA0.10
Interest Coverage-537.37

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A posted a return on equity (ROE) of 5.40, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.64 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.04, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.60, useful for judging operating efficiency across full business cycles. The company generates approximately 844,422.19 in revenue per employee across its workforce of 2,593.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.01 indicates how many times PharmaBlock Sciences (Nanjing), Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)5.40
Return on Assets (ROA)4.04
Return on Invested Capital (ROIC)4.64
Return on Capital Employed (ROCE)4.60
Revenue Per Employee844,422.19
Employee Count2,593.00
Inventory Turnover2.01

Taxes

CNY

Over the twelve months ended September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A recorded 28.92M in income tax expense. That works out to an effective tax rate of 11.55, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 250.49M, leaving 221.56M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax28.92M
Effective Tax Rate11.55

Stock Price Statistics

CNY

As of the close on November 17, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A's stock has gained approximately 6.80% over the past 52 weeks. The 50-day moving average sits at 46.08, while the 200-day moving average is 40.90.

52-Week Price Change6.80%
50-Day Moving Average46.08
200-Day Moving Average40.90

Income Statement

CNY

Over the twelve months ended September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A generated 2.19B in revenue and converted that into 221.56M in net income, yielding earnings per share of 0.96. EBITDA reached 253.93M, while operating income came in at 290.95M.

Revenue2.19B
Gross Profit707.42M
Operating Income290.95M
Pretax Income250.49M
Net Income221.56M
EBITDA253.93M
EBIT253.93M
Earnings Per Share (EPS)0.96

Balance Sheet

CNY

As of September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A holds 1.39B in cash and equivalents against 25.33M in total debt, resulting in a net debt position of -692.79M. Total book value stands at 4.59B, with working capital of 2.03B providing operational flexibility.

Cash & Cash Equivalents1.39B
Total Debt25.33M
Net Debt-692.79M
Equity (Book Value)4.59B
Book Value Per Share19.62
Working Capital2.03B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-375.90M

Margins

Over the twelve months ended September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A posted a gross margin of 32.31, reflecting its pricing power and cost economics. The operating margin of 13.29 and net profit margin of 10.12 provide insight into operational efficiency.

Gross Margin32.31
Operating Margin13.29
Pretax Margin11.44
Profit Margin10.12
EBITDA Margin11.60

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A paid dividends of 0.38 per share. The dividend payout ratio of 39.03 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.44, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PharmaBlock Sciences (Nanjing), Inc. Class A shareholders.

Dividend Per Share0.38
Payout Ratio39.03
Shareholder Yield1.44

Stock Splits

PharmaBlock Sciences (Nanjing), Inc. Class A's most recent stock split took place on April 26, 2021 with a 10:13 split ratio.

Last Split Date4/26/2021
Split Ratio10:13

Scores

As of September 30, 2026, PharmaBlock Sciences (Nanjing), Inc. Class A has an Altman Z-Score of 10.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score10.80